drugset / Trial / NCT07221240

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis

NCT07221240 ↗

Phase 1 Recruiting 48 enrolled PRG Science & Technology Co., Ltd.
RandomizedSequentialSingle-blindTreatment

Summary

Researchers will evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered Amisodin in healthy adult subjects through a randomized, double-blind, placebo-controlled Phase 1 study consisting of two parts: single ascending dose (SAD) and multiple ascending dose (MAD). The food effect will be assessed in one cohort in Part1. Approximately 48 healthy, adult subjects are planned to be enrolled in total. Subjects will participate in only one part and one cohort.

Timeline

Start
2025-10-01
Primary completion
2026-05-27
Completion
2026-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Amisodin Unknown — Oral